# SAfety of Regional Citrate Anticoagulation (SARCA Study)

> **NCT05339139** · PHASE3 · RECRUITING · sponsor: **Fresenius Medical Care North America** · enrollment: 50 (estimated)

## Conditions studied

- Acute Kidney Injury
- ESRD

## Interventions

- **COMBINATION_PRODUCT:** Dialysis

## Key facts

- **NCT ID:** NCT05339139
- **Lead sponsor:** Fresenius Medical Care North America
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-10-17
- **Primary completion:** 2025-04-30
- **Final completion:** 2025-07-31
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2025-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05339139

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05339139, "SAfety of Regional Citrate Anticoagulation (SARCA Study)". Retrieved via AI Analytics 2026-06-29 from https://api.ai-analytics.org/clinical/NCT05339139. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*